As part of our monthly news service we would like to make you aware of the CML publications of the month. From the many papers published every month Professor Timothy Hughes has selected topical, interesting papers for your perusal that also include interesting publications on pediatric CML and publications from low- and middle-income countries.

Read Professor Hughes' CML publications of the month: September 2024

Clinical CML papers

• Perspectives on drug development for the treatment of chronic myeloid leukemia in pregnant patients and patients who are breastfeeding – Reviev
  Cortes JE et al. Clin Cancer Res, Sept 2024
  
• Outcomes of chronic myeloid leukemia patients after therapeutic failure to conventional tyrosine kinase inhibitors and asciminib
  Pérez-Lamas L et al. Ann Hematol, Sept 2024 (epub ahead of print) – open access publication
  
• Overcoming clinical BCR-ABL1 compound mutant resistance with combined ponatinib and asciminib therapy
  Eide CA et al. Cancer Cell, Sept 2024
  
• Choice of frontline tyrosine-kinase inhibitor and early events in very elderly patients with chronic myeloid leukemia in chronic-phase: A “Campus CML” Study
  Bucelli C et al. Eur J Haematol, Sept 2024 (epub ahead of print) – open access publication
  
• Real-world evaluation of treatment patterns and clinical outcomes among patients with chronic myeloid leukemia in chronic-phase treated with asciminib in clinical practice in the US: Real-world asciminib treatment outcomes in CML-CP
  Atallah E et al. Clin Lymphoma Myeloma Leuk, Sept 2024 (epub ahead of print)
  
• Outcome after short exposure to tyrosine kinase inhibitors in pregnant female patients with chronic myeloid leukemia
  Zu Y et al. J Hematol Oncol, Sept 2024 – open access publication
  
• Treatment-free remission as a new goal in the management of chronic myeloid leukemia: Clinical and biological aspects – Review
  Cattaneo D et al. Hematol Oncol, Sept 2024
• Deep molecular response rate in chronic phase chronic myeloid leukemia: Eligibility to discontinuation related to time to response and different frontline TKI in the experience of the Gimema Labnet CML National Network
  Breccia M et al. Clin Lymphoma Myeloma Leuk, Sept 2024 (epub ahead of print)
• Dose justification for asciminib in patients with Philadelphia chromosome positive chronic myeloid leukemia with and without the T315I mutation
  Combes PF et al. Clin Pharmacokinet, Sept 2024 – open access publication
• CML 25 years later – Poised for another breakthrough?
  Abruzzese E. N Engl J Med, Sept 2024
• Imatinib remains the best frontline therapy in patients with chronic myeloid leukemia: Critical analysis of the ASC4First trial
  Srinivasan N et al. Am J Hematol, Sept 2024 (epub ahead of print) – open access publication
• The initial molecular response predicts the deep molecular response but not treatment-free remission maintenance in a real-world chronic myeloid leukemia cohort
  Saugues S et al. Haematologica, Sept 2024 – open access publication
• Triplet therapy for advanced BCR::ABL1 positive myeloid leukemia
  Copland M. Lancet Haematol, Sept 2024 (epub ahead of print)

Scientific CML papers

• The e13a3 (b2a3) and e14a3 (b3a3) BCR::ABL isoforms are resistant to asciminib
  Leske IB and Hantschel O. Leukemia, Sept 2024 – open access publication
• Impact of BCR::ABL1 single nucleotide variants on asciminib efficacy
  Innes AJ et al. Leukemia, Sept 2024 (epub ahead of print) – open access publication
• Absence of ABL1 exon 2-decoded SH3 residues in BCR::ABL1 destabilizes the autoinhibited kinase conformation and confers resistance to asciminib
  Leyte-Vidal A et al. Leukemia, Sept 2024 – open access publication

Pediatric papers

• A high proportion of germline variants in pediatric chronic myeloid leukemia in pediatric chronic myeloid leukemia
  Krumbhold M et al. Mol Cancer, Sept 2024 – open access publication
• CAR-T cells for the treatment of pediatric chronic myeloid leukemia in repeatedly relapsed lymphoid blast crisis
  Kramp LJ et al. Ann Hematol, Sept 2024 (epub ahead of print) – open access publication

LMIC Papers

• Impact of a guaranteed access program to imatinib on the survival of patients with chronic myeloid leukemia
  Barranco G et al. Cancer Causes Control, Sept 2024 (epub ahead of print)
• Late presentation of chronic myeloid leukemia patients in a low-income country: The prognostic implications and impact on treatment outcome
  Nelson EA et al. BMC Res Notes, Sept 2024 – open access publication